|
🐢
|
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.
13 auth.
R. Fleischmann,
Alan Friedman,
E. Drescher,
A. Singhal,
Gregorio Cortes-Maisonet,
Thao T. Doan,
Wenjing Lu,
Zailong Wang,
Ahmed Nader,
William Housley,
...
S. Cohen,
Peter C. Taylor,
R. Blanco
|
2 |
2022 |
2
🐢
|
|
🐜
|
OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial
11 auth.
D. Gladman,
W. Rigby,
V. Azevedo,
F. Behrens,
R. Blanco,
A. Kaszuba,
...
M. KudlaczElizabeth,
Cunshan Wang,
S. Menon,
T. Hendrikx,
K. Kanik
|
2 |
2017 |
2
🐜
|
|
🐜
|
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
14 auth.
Andrew Östör,
Filip E Van den Bosch,
K. Papp,
C. Asnal,
R. Blanco,
J. Aelion,
K. Carter,
V. Stakias,
Ralph Lippe,
L. Drogaris,
...
Ahmed M. Soliman,
Michael M Chen,
Byron Padilla,
A. Kivitz
|
1 |
2024 |
1
🐜
|
